Letter to the Editor Low Molecular Weight Heparin as Thromboprophylaxis Throughout Pregnancy in Heritable Thrombophilic Women
To the Editor:
Thromboembolic complication during pregnancy is the most common cause of maternal death. Throughout pregnancy, anticoagulant administration is indicated for the treatment and prophylaxis of thromboembolic diseases in women with (a) heritable thrombophilia, (b) antiphospholipid-antibody syndrome, and (c) a prosthetic heart valve. Recently, the European Prospective Cohort on Thrombophilia (EPCOT) study proved an increased fetal loss in women with heritable thrombophilia. The risks were greatest for women with antithrombin deficiency and for those with combined defects. In women with factor V factor Leiden the results suggested the possibility of increased risk of stillbirth (1.2% vs. 0.6% of controls) but there was no excess of miscarriages (1) .
Others found second trimester pregnancy loss associated with activated protein C resistance (2) . Heritable deficiencies of the vitamin K-dependent physiological anticoagulants protein C and protein S have recently been associated with an increased risk for gestational abnormalities. The increased risk was significant in particular for intrauterine death (3) . Patients with a deficiency of antithrombin, protein C, or protein S have a 70%, 33%, and 17% incidence of thrombosis during pregnancy, respectively (4) .
Coumarol therapy should be avoided throughout pregnancy. Its use during the first trimester has been associated with a characteristic embryopathy. Pathologic effects on the fetus, like central nervous system and ophthalmologic abnormalities, have been associated with exposure to warfarin in any trimester. Warfarin readily crosses the placenta and can result in fetal and neonatal hemorrhage and placental abruption. Low-dose unfractionated heparin (UFH) has a prophylactic effect, but the long-term UFH administration may be complicated by osteoporosis and/or thrombocytopenia. Low molecular weight heparins (LMWHs) may offer four advantages over UFH during pregnancy: (a) LMWH-induced thrombocytopenia is extremely rare; (b) In spite of long-term use, the risk of heparin-induced osteoporosis may be reduced by the use of LMWHs; (c) LMWHs have longer plasma half-life; and (d) Laboratory control is not necessary. There are no controlled clinical trials with LM-WHs for thromboprophylaxis in pregnancy. However, according to some recent studies LMWH does not cross the placental barrier and the use of LMWH was not associated with adverse fetal outcomes (5-10).
In the last 5 years, 60 pregnancies of 32 pregnant women with heritable thrombophilia were treated and followed by us. Patients were diagnosed with protein C deficiency (5 patients), protein S deficiency (8 patients), APC resistance (8 patients), combined defects (9 patients) ; antithrombin deficiency with APC resistance [3] , protein C deficiency with APC resistance [2] , protein S deficiency with APC resistance [3] , and 1 case with protein C and protein S deficiencies, and antiphospholipidantibody syndrome (2 patients). Every patient had thrombosis in her case history, therefore they were treated with coumarol before pregnancies. There were 23 pregnancies without any thromboprophylaxis. UFH (Heparibene-Ca 0.3 mL twice daily) was given in 11 patients, and 26 cases were treated with LMWH (Fraxiparine) throughout the pregnancies. The doses of Fraxiparine were in the range of 0.2 mL (2,050 IU) once daily and 0.6 mL (6,150 IU) twice daily. Fraxiparine dosage was based on the patient's bodyweight. The period of pregnancy (the doses were increased in the second or third period of the pregnancies in cases with protein C or protein S deficiency), and the type of thrombophilia (in cases with antithrombin deficiency or combined defect higher doses were applied). We changed coumarol to Fraxiparine 1 month before pregnancy and continued LMWH treatment for 1 week after delivery.
Outcomes of pregnancies: (a) Without anticoagulant prophylaxis the ratio of successful pregnancies was 4 (17.4%) of 23. Of the 23 pregnancies there were 18 miscarriages and 1 intrauterine fetal death. During the pregnancies three patients had deep venous thrombosis. (b) With UFH prophylaxis the ratio of successful pregnancies was 8 (72.7%) of 11. In 3 patients intrauterine dead fetal syndrome was realized. (c) With LMWH (Fraxiparine) prophylaxis the ratio of successful pregnancy was 24 (92.3%) of 26 (Table 1 ) and there were two miscarriages. In the patient group treated with Fraxiparine there was no foetopathy, thrombocytopenia, or bleeding complication.
LMWH is a suitable anticoagulant recommended for pregnant women with thrombophilia throughout pregnancy. Randomized, controlled multicentric, clinical study is needed to determine the exact dose of LMWH as 
